Moleculin Biotech CS (MBRX)

$0.49 0.00 (-0.90%)
Market Cap 24.27M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,953,600
Avg Vol 3,393,164
Day's Range N/A - N/A
Shares Out 49.50M
Stochastic %K 51%
Beta 1.59
Analysts Strong Sell
Price Target $6.67

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: (713) 300-5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
IVALTE
IVALTE Oct. 25 at 1:00 PM
$MBRX Is not sense to be $0,50 while experts said that can reach $4
0 · Reply
Stormra
Stormra Oct. 24 at 1:58 PM
$MBRX
0 · Reply
Stormra
Stormra Oct. 24 at 1:57 PM
$MBRX https://www.tipranks.com/news/ratings/moleculin-biotechs-promising-drug-pipeline-and-strategic-expansion-justify-buy-rating-ratings $INO $TRNR $AREB
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 5:20 PM
GIPR about to breakout! The combo is rare – Real assets – Strong tenant quality – Undervalued structure – No dilution is bottomed, coiled, and ready. Chart compression like this always leads to a decision and the upside is wide. $PRFX $SNMP $NAOV $MBRX $ADTX
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 4:51 PM
If you’re seeking asymmetric upside, check out GIPR. It’s trading at a steep discount to what its asset base suggests, with few eyes on it and potential for a rerate if narrative shifts. This could be the hidden gem in the REIT space. $MBRX $VTEX $RR $EJH
0 · Reply
MessiMagic
MessiMagic Oct. 23 at 2:12 PM
$MBRX this news will attract more investors and also bring more confidence. Let’s see what happens!
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:36 PM
$MBRX 09:28 on Oct. 23 2025 Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer #tradeideas
0 · Reply
Stormra
Stormra Oct. 23 at 1:33 PM
$MBRX Yes! Yes! Yes!
0 · Reply
Stormra
Stormra Oct. 23 at 1:13 PM
$MBRX Moleculin Biotech Enters Collaboration With Atlantic Health On An Investigator-Initiated Phase 1B/2 Study To Evaluate Its Drug Candidate Annamycin As A Third-Line Treatment For Advanced Pancreatic Cancer. $AREB $INO $TRNR
0 · Reply
Stormra
Stormra Oct. 23 at 1:10 PM
$MBRX Reuters 24 minutes ago Oct 23 (Reuters) - Moleculin Biotech Inc (MBRX.NaE): * MOLECULIN ANNOUNCES NEW INVESTIGATOR-INITIATED STUDY OF ANNAMYCIN FOR TREATING PANCREATIC CANCER * MOLECULIN BIOTECH INC (MBRX.NaE) - ESTIMATES TRIAL COST AT $1.X MILLION FROM 2026 TO 2030 Source text: Further company coverage:
0 · Reply
Latest News on MBRX
Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Oct 23, 2025, 8:00 AM EDT - 2 days ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 25, 2025, 8:35 AM EDT - 4 weeks ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 9, 2025, 8:45 AM EDT - 6 weeks ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 2 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 2 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:05 AM EDT - 2 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Aug 6, 2025, 8:40 AM EDT - 2 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 3 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 3 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 3 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 3 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 4 months ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:45 AM EDT - 4 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 18, 2025, 7:30 AM EDT - 4 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 5, 2025, 8:00 AM EDT - 5 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 5 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:20 PM EDT - 5 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 5 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025, 8:40 AM EDT - 5 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025, 9:00 AM EDT - 6 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025, 9:00 AM EDT - 6 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025, 8:45 AM EDT - 6 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 29, 2025, 8:35 AM EDT - 6 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 17, 2025, 8:30 AM EDT - 6 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Apr 1, 2025, 8:30 AM EDT - 7 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 10:50 AM EDT - 7 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 7 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 19, 2025, 8:05 AM EDT - 7 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 8 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 8 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 6, 2025, 8:30 AM EST - 8 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Mar 3, 2025, 8:30 AM EST - 8 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 25, 2025, 12:35 PM EST - 8 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:19 PM EST - 9 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 1:05 PM EST - 9 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 13, 2025, 9:25 AM EST - 9 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Feb 11, 2025, 8:40 AM EST - 9 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 27, 2025, 8:30 AM EST - 9 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Jan 8, 2025, 8:30 AM EST - 10 months ago

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Dec 11, 2024, 8:00 AM EST - 11 months ago

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Nov 18, 2024, 8:15 AM EST - 1 year ago

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Nov 14, 2024, 8:15 AM EST - 1 year ago

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Nov 12, 2024, 8:00 AM EST - 1 year ago

Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 11:17 AM EST - 1 year ago

Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 11, 2024, 7:05 AM EST - 1 year ago

Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Nov 5, 2024, 9:00 AM EST - 1 year ago

Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Nov 4, 2024, 8:30 AM EST - 1 year ago

Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

Oct 17, 2024, 8:40 AM EDT - 1 year ago

Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available

IVALTE
IVALTE Oct. 25 at 1:00 PM
$MBRX Is not sense to be $0,50 while experts said that can reach $4
0 · Reply
Stormra
Stormra Oct. 24 at 1:58 PM
$MBRX
0 · Reply
Stormra
Stormra Oct. 24 at 1:57 PM
$MBRX https://www.tipranks.com/news/ratings/moleculin-biotechs-promising-drug-pipeline-and-strategic-expansion-justify-buy-rating-ratings $INO $TRNR $AREB
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 5:20 PM
GIPR about to breakout! The combo is rare – Real assets – Strong tenant quality – Undervalued structure – No dilution is bottomed, coiled, and ready. Chart compression like this always leads to a decision and the upside is wide. $PRFX $SNMP $NAOV $MBRX $ADTX
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 23 at 4:51 PM
If you’re seeking asymmetric upside, check out GIPR. It’s trading at a steep discount to what its asset base suggests, with few eyes on it and potential for a rerate if narrative shifts. This could be the hidden gem in the REIT space. $MBRX $VTEX $RR $EJH
0 · Reply
MessiMagic
MessiMagic Oct. 23 at 2:12 PM
$MBRX this news will attract more investors and also bring more confidence. Let’s see what happens!
0 · Reply
DARKP00L
DARKP00L Oct. 23 at 1:36 PM
$MBRX 09:28 on Oct. 23 2025 Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer #tradeideas
0 · Reply
Stormra
Stormra Oct. 23 at 1:33 PM
$MBRX Yes! Yes! Yes!
0 · Reply
Stormra
Stormra Oct. 23 at 1:13 PM
$MBRX Moleculin Biotech Enters Collaboration With Atlantic Health On An Investigator-Initiated Phase 1B/2 Study To Evaluate Its Drug Candidate Annamycin As A Third-Line Treatment For Advanced Pancreatic Cancer. $AREB $INO $TRNR
0 · Reply
Stormra
Stormra Oct. 23 at 1:10 PM
$MBRX Reuters 24 minutes ago Oct 23 (Reuters) - Moleculin Biotech Inc (MBRX.NaE): * MOLECULIN ANNOUNCES NEW INVESTIGATOR-INITIATED STUDY OF ANNAMYCIN FOR TREATING PANCREATIC CANCER * MOLECULIN BIOTECH INC (MBRX.NaE) - ESTIMATES TRIAL COST AT $1.X MILLION FROM 2026 TO 2030 Source text: Further company coverage:
0 · Reply
Whales22
Whales22 Oct. 23 at 5:59 AM
How much volume do you think it takes to Gap BBGI up? BBGI has not even 700k shares float and recent news. Hoping for a 100% run on BBGI $AZTR $GIS $TNON $MBRX Watchlist!
0 · Reply
Waja215
Waja215 Oct. 22 at 8:00 PM
$MBRX
0 · Reply
IVALTE
IVALTE Oct. 22 at 7:42 PM
$MBRX teleleco
0 · Reply
aj_hollins
aj_hollins Oct. 22 at 4:13 PM
$MBRX no public news yet on their site for October - praying we get something by next Friday (10/31).
0 · Reply
jkgyuool
jkgyuool Oct. 22 at 4:11 PM
$MBRX they want their money and they don’t care how much damage they do to the share price. Bastards.
1 · Reply
teedatrader
teedatrader Oct. 22 at 3:22 PM
$MBRX market is looking like TRASH - let's get an atmospheric squeeze to have some fun.
0 · Reply
Zdxss1
Zdxss1 Oct. 22 at 9:38 AM
$MBRX Pumping a million shares into the market. There is no reason to pump a million shares at such a low price at such a sensitive time other than to push the stock down. Who benefits from this?
0 · Reply
stockusfrance
stockusfrance Oct. 22 at 5:55 AM
$MBRX Interested but they are Going to do dilution imo
0 · Reply
Zdxss1
Zdxss1 Oct. 21 at 8:28 PM
$MBRX We have to wait for the 64 million shares offered to be registered on the Nasdaq. It will take two weeks, and we might see a rise in the share price by the end of next week. The Nasdaq serves the big fish, so you should follow it.
2 · Reply
makedatbread88
makedatbread88 Oct. 21 at 5:49 PM
$MBRX this one is dirt dirt cheap here and can be a squeeze candidate bottom looks in on this one
0 · Reply
aj_hollins
aj_hollins Oct. 21 at 1:57 PM
$MBRX patience <3
0 · Reply
Blocktatch
Blocktatch Oct. 20 at 12:20 PM
$MBRX today!!!!!!!
0 · Reply